IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the
ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the
efficacy of AA. To date, no previous studies have investigated the therapeutic role of AA in
peritoneal metastatic colorectal cancer with high expression of GLUT3. This protocol is a
randomized controlled study of AA infusions combined with FOLFOXIRI +/- bevacizumab versus
treatment with FOLFOXIRI +/- bevacizumab alone in peritoneal metastatic colorectal cancer
patients with high expression of GLUT3.